

TOPCEF DT

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.

Abbreviated Prescribing information for Topcef DT (Cefixime dispersible Tablets)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: The bactericidal action of cefixime is due to the inhibition of cell wall synthesis. It binds to one of the penicillin binding proteins (PBPs) which inhibits the final transpeptidation step of the peptidoglycan synthesis in the bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.

DOSAGE AND ADMINISTRATION:

Adults and Children over 10 Years or weighing more than 50 kg:

The recommended adult dosage is 200-400 mg daily according to the severity of infection, given either as a single dose or in two divided doses. Topcef DT is not recommended for use in children under 10 years old.

Elderly:

Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed and dosage should be adjusted in severe renal impairment

CONTRAINDICATION: Known hypersensitivity to cephalosporin antibiotics or to any of the excipients.

WARNINGS & PRECAUTIONS: Encephalopathy, severe cutaneous adverse reactions, haemolytic anaemia, acute renal failure.

DRUG INTERACTION: It can interact with coumarin-type anticoagulants, e.g. warfarin potassium. Since cefixime may enhance effects of the anticoagulants, prolonged prothrombin time with or without bleeding may occur.

ADVERSE REACTIONS: Eosinophilia, hypereosinophilia, agranulocytosis, leucopenia, neutropenia, granulocytopenia, haemolytic anaemia, thrombocytopenia, thrombocytosis, abdominal pain, diarrhea, jaundice, pseudomembranous colitis, abnormal hepatic function tests, convulsion, encephalopathy, renal failure acute including tubulointerstitial nephritis, anaphylactic reaction, serum sickness-like reaction, drug rash with eosinophilia and systemic symptoms (DRESS), pruritus, rash, drug fever, arthralgia, erythema multiforme, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis, angio-oedema, urticaria, pyrexia, face oedema, genital pruritus, vaginitis.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/TOPCEF DT 50mg, 100mg/Apr-2020/01/ABPI

(Additional information is available on request)